The Technology
Treatments for bone-related diseases are limited due to significant side effects, lack of effective disease management, drug challenges, bone barrier leading to low drug concentration in bone. Bone marrow-targeted liposomes (BMTL) represent a novel nanomedicine platform designed to enhance the delivery of therapeutic agents specifically to the bone. This technology utilizes nanoparticles conjugated with AMD3100 (Plerixafor®), a CXCR4 antagonist, enabling precise targeting of CXCR4-expressing cells mostly found in the bone.
BMTL serves as a versatile platform for encapsulating a variety of drugs, improving treatment specificity, and reducing systemic toxicity. Preclinical studies in multiple myeloma (MM) models have demonstrated highly effective therapy of BMTL compared to free drugs, significantly and substantially reducing tumor burden and associated side effects.
Beyond multiple myeloma, BMTL has potential applications in other bone-related diseases, such as bone metastases, hematologic malignancies, osteosarcoma, and osteoporosis, offering a transformative approach to therapeutic delivery in the bone microenvironment.
Advantages
- Enhanced drug specificity through CXCR4 targeting.
- Reduced systemic toxicity and improved safety profile.
- Prolonged pharmacokinetics with fewer required administrations.
- Demonstrated efficacy in reducing tumor burden in preclinical MM models.
- Potential companion diagnostic capabilities for CXCR4-associated diseases.
Applications
- Bone Marrow Diseases: Multiple myeloma, acute myeloid leukemia, and other hematologic malignancies.
- Bone Metastases: Targeted treatment of metastatic cancers involving bone tissue.
- Osteosarcoma and Osteoporosis: Enhanced therapeutic strategies for primary bone tumors and degenerative bone diseases.
- Companion Diagnostics: Identifying patients with CXCR4-associated conditions for precision medicine approaches.
Business Development Contacts